PHOSPHO1 and tissue-nonspecific alkaline phosphatase (TNAP) have non-redundant functions during skeletal mineralization. While TNAP deficiency (Alpl -/mice) leads to hypophosphatasia, caused by accumulation of the mineralization inhibitor inorganic pyrophosphate (PP i ), comparably elevated levels of PP i in Phospho1 -/mice do not explain their stunted growth, spontaneous fractures, bowed long bones, osteomalacia, and scoliosis. We have previously shown that elevated PP i in Alpl -/mice is accompanied by elevated osteopontin (OPN), another potent mineralization inhibitor, and that the amount of OPN correlates with the severity of hypophosphatasia in mice.
INTRODUCTION
PHOSPHO1 is active in the cytosol of osteoblasts and chondrocytes, as well as in their derived matrix vesicles (MVs), where it participates in MV-mediated calcification. 1, 2 Our recent studies have shown that PHOSPHO1 and tissue-nonspecific alkaline phosphatase (TNAP) play non-redundant functional roles in skeletal and dental mineralization. [3] [4] [5] PHOSPHO1 participates in the initiation of hydroxyapatite (HA) deposition inside MVs by scavenging P i from phosphoethanolamine and phosphocholine, the head groups of the major phospholipids that constitute the plasma membrane of MVs, while TNAP facilitates propagation of HA crystals outside the MVs by restricting the concentrations of inorganic pyrophosphate (PP i ), a potent calcification inhibitor. [3] [4] [5] Remarkably, the double ablation of the PHOSPHO1 and TNAP function in our mouse model, leads to the complete absence of skeletal and dental mineralization in mice. 3, 6 Lack of murine PHOSPHO1 causes slow growth and skeletal deformities that include low bone mineral density, spontaneous greenstick fractures, osteomalacia, and prominent scoliosis. 3, 4 Both levo-and dextro-scoliosis is observed in Phospho1 -/mice, but µCT ruled out the presence of any obvious morphological abnormalities, such as hemivertebrae or fused vertebrae. 3 Biochemically, Phospho1 -/mice show elevated levels of plasma PP i , a change that is also observed in mice deficient in TNAP (Alpl -/-), which manifest the soft bones disease known as hypophosphatasia (HPP). Indeed, correcting PP i levels in Alpl -/mice, either via cross-breeding Alpl -/mice to a transgenic strain expressing human TNAP under control of the ApoE promoter, [Alpl -/-; ApoE-ALPL], 7 or via enzyme-replacement therapy with a mineral-targeting recombinant form of TNAP, 8 completely prevents the development of the skeletal and dental abnormalities characteristic of this mouse model of infantile HPP. However, reducing the PP i levels in Phospho1 -/mice by cross-breeding them to the same ApoE-ALPL transgenic mice, did not significantly improve the skeletal phenotype of Phospho1 -/mice. 3 Osteopontin (OPN, encoded by Spp1) is another potent inhibitor of mineralization that is highly expressed in osteoblasts, as well as in osteoclasts. [9] [10] [11] [12] OPN is an Arg-Gly-Asp motif-containing matricellular protein 13 that contains several putative phosphorylation sites 14 and that can inhibit hydroxyapayite deposition in vitro when phosphorylated. 9 Furthermore, phosphorylation-dependent inhibition of mineralization by OPN appears to be mediated by ASARM peptides released from OPN by phosphate regulating endopeptidase homolog, X-linked (PHEX) cleavage. 15 Spp1 -/mice have a skeleton that is histologically similar to WT mice and that is normal, even slightly hypermineralized. 16, 17 OPN expression is regulated by extracellular concentrations of PP i ; [18] [19] [20] indeed, there is a linear correlation between PP i and OPN concentrations in mutant mouse strains displaying dysregulation of PP i metabolism, such as Alpl -/-, Enpp1 -/and ank/ank mice. 17 However, ablating Spp1 in an Alpl null background only partially rescued the HPP phenotype, confirming that the elevated PP i concentrations caused the HPP and that OPN only contributed partially to this phenotype. 17 Given the increased levels of plasma PP i observed in Phospho1 -/mice, we surmised that OPN levels would also be elevated in this mutant strain and that elevated OPN concentrations might contribute to the skeletal defects in this model of skeletal dysplasia. Remarkably, as shown in the present study, ablating Spp1 function prevents the development of the skeletal phenotype of Phospho1 -/mice, establishing a primary role for OPN, rather than PP i , in the pathophysiology of the Phospho1 -/skeletal defects.
MATERIALS AND METHODS

Mice
Phospho1-R74X null mutant (Phospho1 -/-) mice were generated by N-ethyl-N-nitrosourea mutagenesis in a C3HeB/FeJ (Stock No. 000658, Jackson Laboratories, Bar Harbor, ME, USA) background, then bred to C57BL/6 mice to segregate other possible undesired mutations. 3 Spp1 -/mice were generated in a C57BL/6 background. 21 Founder Spp1 -/mice were imported from Japan (kindly provided by Prof. Masaki Noda) and re-derived into C57BL/6 mice. The resulting progeny were bred to obtain Spp1 +/− mice and the colony was maintained by heterozygote breeding. To generate mice lacking both PHOSPHO1 and OPN, Phospho1 -/mice were crossed to Spp1 -/mice and double heterozygote mice were used to generate [Phospho1 -/-; Spp1 -/-] mice. The Phospho1 -/genotypes were determined using genomic DNA, PCR and restriction digestion by BsrDI and Spp1 -/genotypes were determined using genomic DNA and PCR protocols. 3, 18 The primer sequences for Phospho1 genotyping were: sense 5 ′ -TCCTCCTCACCTTCGACTTC-3′, antisense 5′-ATGCGGCGGAATAAACTGT-3′. Primer sequences for Spp1 genotyping were: sense 5 ′ -AGAGGTGAGGTCCTCATCTGTGGCA-3′ and antisense 5′-ACTCCAATCGTCCCTACAGTCGATGTC-3′. All animal procedures were reviewed and approved by our Institutional Animal Review Committee (Animal Use Form #12-114, Approval Date: 10/19/12).
Tissue and plasma collection, histological studies and biochemical assays
Mice were euthanized by intraperitoneal injection of tribromoethanol and blood was collected by cardiac puncture.
Whole-body, long bone and spine radiographic images were taken using an MX20 Specimen Radiograph System (Faxitron X-ray Corporation, Chicago, IL) at 1-and 3-months of age. The lumbar spines, tibias, and femurs of 1month-and 3-month-old mice were fixed in PBS containing 4% (w/v) paraformaldehyde. Plastic sections were stained with Von Kossa/van Gieson stain using published procedures 7, 8, 22 and these sections were used to quantify osteoid volume using Bioquant Osteo Software (Bioquant Osteoanalysis Co., Nashville, TN).
For OPN immunohistochemistry, bone tissues were decalcified with 0.125 M EDTA/10% formalin in H 2 O (pH 7.2) for five days after fixation, and processed for paraffin sectioning. Immunostaining for OPN was performed using a goat anti-mouse-OPN antibody, Cambridge, MA) and a standard avidin-biotin complex protocol, using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA).
Blood was collected by cardiac puncture and transferred into lithium heparin tubes. Plasma was separated by centrifugation at 5,000 rpm for 10 min. Alkaline phosphatase activity and PP i concentrations in plasma were measured using previously reported methods. 8 For PP i assay, plasma was heated at 65 °C for 10 min, 10 µl of plasma was diluted 4 times and PP i was measured by differential adsorption on activated charcoal of UDP-D- [6- 3H]glucose (Amersham Pharmacia, Piscataway, NJ), as previously described. 18, 23 
Micro-computed tomography (µCT)
Mice were euthanized at 1-and 3-months of age, as above, and the tibiae and femur were dissected and stored in water at −20°C. μCT analysis of the trabecular bone was performed on a 2-mm section of the right tibial and femoral metaphyses, 250 μm distal to the growth plate, using a Skyscan 1172 instrument (Kontlich, Belgium) set at 60 kV, 150 μA and a resolution of 5 μm. Cortical analysis was conducted on a 250-μm section located 2.25 mm distal to the reference growth plate. The spines were dissected from the cervical to the second lumbar vertebrae and the thoracic vertebrae were scanned at a resolution of 20 μm. The images were reconstructed using the Skyscan NRecon program, analyzed using Skyscan CTAn and the 3D models were visualized in Skyscan CTvol software. 3
Mineralization assay and gene expression analysis
Primary chondrocytes were isolated from the knee joint growth plates of five-day-old pups by collagenase digestion, as described previously. 3 Mineralization assays were performed by growing the cells in the presence of 2.5 mM β-glycerolphosphate and 50 mM ascorbic acid for 21 days and then staining with Alizarin red using a standard method . RNA was extracted using an RNAeasy Plus Kit (Qiagen, Valencia, CA, USA). Specific RNA transcripts (mRNA) for Alpl, Enpp1, Col2a1, Col10a1, Nr4a2, Mmp13, Phospho1 and Acan were quantified by real-time PCR using dual-labeled hydrolysis probes (FAM-TAMRA), as described previously. 3 Briefly, to carry out quantitative real time PCR, 2 µL of the (1:10) diluted cDNA was used for assaying the amount 
Western blot and mass spectrometry analysis
After removal of skin, tendons and muscle, leg and spine bones were snap frozen with dry ice and frozen bones were crushed into powder. The crushed bones, and chondrocytes cultured for 21 days in mineralization media as described above, were suspended in lysis solution (4 M guanidine HCl, 50 mM Tris HCl, 0.5 M EDTA, 2 mM phenylmethysulphonylfluoride, 5 mg/l pepstatin and 1 mg/l soybean trypsin inhibitor; pH 7.5). 24 After rotation at 4°C for 48 hours, the samples were dialyzed against Tris-buffered saline solution containing 5 mM EDTA and 2 mM phenylmethysulphonylfluoride (pH 7.5) at 4°C to remove guanidine salt. Protein concentration was determined using a bicinchoninic acid assay kit according to manufacturer's instructions (Thermo Fisher Scientific Inc., Rockford, IL, USA). SDS-PAGE was performed as before. 25 OPN was detected using a goat anti-mouse-OPN antibody (Abcam, Cambridge, MA) and the ECL Plus kit (GE Healthcare, Pittsburgh, PA).
For proteomic analysis, samples were prepared as previously described. 25 
OPN dephosphorylation by TNAP and PHOSPHO1, and phosphate release assay
This assay was performed using a passive adsorption method on latex beads (Life Technologies, Carlsbad, CA)
according to the manufacturer's instructions. Briefly, latex beads were incubated with goat polyclonal antibody against mouse OPN (Abcam, Cambridge, MA) overnight at 4°C. The beads were then washed and blocked with 1% (w/v) bovine serum albumin and incubated with plasma from WT mice, as a source of OPN. After washing, the beads were incubated with buffer as a negative control, recombinant TNAP (0.225 µM and 0.112 µM) and PHOSPHO1 (6.666 µM and 3.333 µM) and TNAP and PHOSPHO1 combined (0.112 µM TNAP and 3.333 µM PHOSPHO1) in separate reactions. The phosphate released into the supernatant was measured using the P i ColorLock Gold phosphate detection system (Innova Biosciences, Cambridge, UK) according to the manufacturer's protocol and absorbance was read at 630 nm. A phosphate (P i ) standard curve was generated and readings taken at 5, 15 and 30 minutes of incubation showed a plateau in P i concentration generated by TNAP at 30 minutes. Therefore, the reaction was monitored in the linear phase between 5 and 15 min and the calibration line at 15 minutes was corrected for the baseline and used to convert ΔA 630 nm over 10 minutes in P i concentrations.
Calibrations were then done taking the concentration of TNAP and PHOSPHO1 into account and the apparent rate constants, expressed per s, were calculated.
Statistical analysis
All measurements were performed at least in triplicate. Results are expressed as mean ± Standard Error of the Mean (SEM). The data were analyzed using Student's t test and p values less than 0.050 were considered significant.
RESULTS
Elevated osteopontin in the spine and plasma of Phospho1 −/− mice
Immunohistochemistry demonstrated higher expression of OPN in the spine of 1-month-old Phospho1 −/− mice than in the spine of WT littermate control mice ( Fig. 1A) , while no change in OPN expression was observed in their femurs ( Fig. 1B) . Significantly higher levels of OPN were also observed in the plasma of both 1-and 3-month-old Phospho1 −/− mice than in WT mice (1-month-old, WT = 165.1 ± 11.21 ng/ml, Phospho1 -/-= 203.9 ± 12.65 ng/ml, p=0.03, n=11; 3-months-old, WT = 94.90 ± 13.33 ng/ml, Phospho1 -/-= 138.7 ± 13.55 ng/ml, p=0.03 n=7) (Fig. 1C ).
Similar results were found at the mRNA level, where quantitative real time PCR showed that Spp1 expression was 2.3-fold higher in the spine of Phospho1 -/mice than in WT mice [WT = 0.9240 ± 0.1314 (N=5); Phospho1 -/-= 2.130 ± 0.4519 (N=4), p=0.025], while no differences were observed in the femur [WT = 1.635 ± 0.3323 (N=6); 1D ). Since PP i is known to affect Spp1 expression, [18] [19] [20] we quantified the expression of Enpp1 in the spine and legs and found higher Enpp1 mRNA levels in the spine in all genotypes (Supplemental Fig. 1 ). Western blot analysis confirmed the higher expression of OPN in the spine of The aforementioned accumulation of p-OPN peptides could be due to lack of phosphatase activity of PHOSPHO1 or could be caused by the reduction in TNAP activity previously documented in Phospho1 -/mice. 3 To clarify this issue, we used passive adsorption of OPN onto latex beads and tested dephosphorylation by recombinant PHOSPHO1 and TNAP and then measured phosphate release by a colorimetric assay. The concentration of released P i in the supernatants, using 0.22 µM TNAP and 6.66 µM PHOSPHO1, was 5.16 µM and 0.77 µM, respectively. The P i release using both TNAP and PHOSPHO1 at half of the concentration of enzymes (0.112 µM and 3.33 µM for TNAP and PHOSPHO1, respectively) was only 0.97 µM. This shows that there is no synergy between both enzymes; the amount of phosphate release with both TNAP and PHOSPHO1 together essentially corresponds to the activity expected for TNAP alone. The mean apparent rate constants for antibody-bound OPN hydrolysis by TNAP and PHOSPHO1 were 3.4 × 10 −2 /s and 8 × 10 −5 /s, respectively. The ratio between the rate constants for both enzymes was 424, which shows that TNAP is about 400 times more active in OPN dephosphorylation than PHOSPHO1. Histomorphometric analyses using Von Kossa/van Gieson staining confirmed that the osteomalacia previously reported in 10-day-old Phospho1 -/mice 3 persisted at 1 month (Supplemental Fig. 2 ) and 3 months of age ( Fig. 3 , arrows). The vertebral sections also showed the presence of widespread hyperosteoidosis in the Phospho1 -/mice (Supplemental Fig. 2 and Fig. 3, arrows) . The osteomalacia in the vertebrae and the long bones of [Phospho1 -/-; Spp1 -/-] mice was somewhat reduced at 1 month of age and significantly at 3 months of age compared to Phospho1 -/mice ( Fig. 3 and Supplemental Fig. 2 ). The significance of the comparison of percentage osteoid volume to bone volume (OV/BV %) measured in the tibiae at 1 month of age were: WT versus Phospho1 -/-, p= 0.035, (N=4) and
Rescue
Phospho1 -/versus [Phospho1 -/-; Spp1 -/-], p=0.043, (N=4) and for vertebral OV/BV%: WT versus Phospho1 -/-, p=0.004, (N=4) and Phospho1 -/versus [Phospho1 -/-; Spp1 -/-] , p=0.003, (N=4). Similarly at 3 months of age the significance for tibial OV/BV % differences were: WT versus Phospho1 -/-, p=0.009, (N=4) and Phospho1 -/versus [Phospho1 -/-; Spp1 -/-], p=0.02, (N=4) and for vertebral OV/BV%: WT versus Phospho1 -/-, p=0.0007, (N=4) and
Phospho1 -/versus [Phospho1 -/-; Spp1 -/-], p=0.0008, (N=4). Scoliosis was observed at 1 month, as shown before 3 , and 3 months (Fig. 4A) of age in the Phospho1 -/mice by µCT where the top thoracic vertebrae (T2 to T4) appear rotated in their axis. Scoliosis was observed in the [Phospho1 -/-; Spp1 -/-] mice at 1 month of age, but not at 3 months of age ( Fig. 4A) .
At one month of age, trabecular analysis of the tibia and femur of Spp1 -/mice showed parameters comparable to WT mice (Supplemental Tables 1 and 2 ). However, at three months of age, Spp1 -/mice showed significantly higher trabecular bone volume per selected area of tissue volume (% BV/TV) than WT mice in both femora (WT = 11.58 ± 1.607, Spp1 -/-= 25.23 ± 3.009, p=0.0035) and tibiae (WT = 9.697 ± 1.852, Spp1 -/-= 19.32 ± 2.796, p=0.016), which reflects the larger trabecular number and lower trabecular space measured ( Fig. 4B, and Supplemental 4D and 4E ). Cortical bone mineral densities (BMD) (Fig. 5A, B) of both femora and tibiae of 1-month-old mice were lower in Phospho1 -/mice than in WT mice, but were significantly higher in [Phospho1 -/-; Spp1 -/-] than in Phospho1 -/mice (WT= 1.21 ± 0.02 g/cm 3 , Phospho1 -/-= 1.09 ± 0.017 g/cm 3 , WT versus Phospho1 -/-, p=0.003, Spp1 -/-= 1.23 ± 0.013 g/cm 3 , [Phospho1 -/-; Spp1 -/-] =1.17 ± 0.01 g/cm 3 , Phospho1 -/versus [Phospho1 -/-; Spp1 -/-], p=0.006) (Figs. 5A and 5B). No significant difference was observed between Spp1 -/and WT mice. The BMD of the tibia and femur at 3 months of age did not show any significant differences between WT, Phospho1 -/and [Phospho1 -/-; Spp1 -/-] mice (Figs.5A and 5B).
In vitro chondrocyte mineralization and plasma analysis
In order to check the mineralization ability of primary chondrocytes, cells from WT, Phospho1 -/-, Spp1 -/and [Phospho1 -/-; Spp1 -/-] mice were grown in culture for 14 and 21 days in the presence of mineralization medium containing ascorbic acid and β-glycerolphosphate. Similar results were obtained both at day 14 (data not shown) and day 21 of culture ( Fig. 6 ). Phospho1 -/and Spp1 -/cells showed lower mineralization than WT cells while (Fig. 6E) . As TNAP hydrolyzes the mineralization inhibitor PP i , we determined plasma PP i levels in 3-month-old mice. Consistent with the measured TNAP levels and our previous reports, 3, 17 we observed high PP i levels in Phospho1 -/and Spp1 -/animals, while the
DISCUSSION
We have previously shown that PHOSPHO1 has a non-redundant function in the initiation of calcification, as Phospho1 -/mice have spontaneous fractures, bowed long bones, osteomalacia, and scoliosis, 3 with approximately 30-40% of Phospho1 -/mice showing thoracic scoliosis on postnatal day 10, and 100% of them having the top thoracic vertebrae (T2 to T4) rotated in their own axis at 1 month of age. However, the skeletal abnormalities in Phospho1 -/mice could not be explained by increased levels of the mineralization inhibitor PP i , because normalizing PP i concentrations did not prevent their skeletal phenotype. 3 Interestingly, Moreau and collaborators showed that high circulating levels of OPN were associated with idiopathic scoliosis onset and spinal deformity progression. 26 OPN is another potent inhibitor of mineralization. 16, 27, 28, 29, 30 It is a matricellular protein that modulates cellmatrix interactions and cell function, 11 without having a structural role itself, 31 and is highly associated with mineralized tissue. 24 Although Spp1 -/mice are both histologically and radiographically normal, 32 there are reports that suggest that OPN has an inhibitory function in mineralization. 16, 27, 28, 29, 30 Recently, we reported that OPN is a physiological substrate of TNAP, and identified at least two preferred sites of dephosphorylation by TNAP. 25 We also documented that the levels of plasma OPN correlated with the severity of the HPP phenotype in Alpl -/mice. 25 Given that PP i induces OPN expression 17, 19, 20 and the strict positive correlation that we had found between PP i and OPN plasma levels in various knockout mouse strains, 17 we tested the hypothesis that ablating OPN function would prevent the skeletal phenotype, particularly the scoliosis, in Phospho1 −/− mice. Indeed, deletion of OPN on the Phospho1 −/− background, [Phospho1 -/-; Spp1 -/-], prevented the scoliosis phenotype and, to some extent, the HPP-like osteomalacia phenotype of Phospho1 -/mice. The differential effect of this improvement is likely due to the much higher levels of Spp1 expressed in the axial versus the appendicular skeleton. In turn, our findings that Enpp1 expression is also much higher in the axial compared to the appendicular skeleton suggests that local differences in the levels of PP i may be responsible for the site-specific regulation of OPN expression. As we recently demonstrated that TNAP physiologically dephosphorylates OPN and affects the ability of OPN to inhibit mineralization, we further hypothesized that PHOSPHO1 can also act as a phosphatase and dephosphorylate OPN and this explains the improvement observed in the [Phospho1 -/-; Spp1 -/-] mice. This would also explain the greater proportion of phosphorylated OPN peptides observed in Phospho1 -/mice than in WT mice. However, we found that PHOSPHO1 dephosphorylates OPN inefficiently, suggesting that the reduction in TNAP activity previously documented in Phospho1 -/mice 3 causes the accumulation of p-OPN in this animal model. OPN triggers Alpl gene expression through αvβ3 integrin-mediated FAK activation 33 so Alpl gene expression is reduced in the absence of OPN. Our findings that Spp1 -/vertebrae, long bones and cultured chondrocytes also show low expression of Phospho1 -/adds Phospho1 to the list of genes that are regulated by OPN, which already includes including Alpl, Enpp1, and Ank. 17 Figure 7 summarizes our current understanding of the complex counter-regulatory influence of the P i /PP i ratio,
OPN and now also PHOSPHO1 on mineralizing cells. While PP i has a major role in controlling deposition in the ECM, changes in the extracellular P i /PP i ratio, likely sensed by sodium-dependent phosphate transporters (P i T1 and/or 2), 34 affect expression of the genes that control the levels of extracellular PP i (Enpp1, Ank, Alpl), as well as OPN. In turn, OPN, especially as p-OPN, 16, 27, 28, 29, 30 participates in controlling hydroxyapatite deposition in the ECM while also influencing the expression of Enpp1, Ank and Alpl, 17 as well as Phospho1. PHOSPHO1 appears to control the expression of OPN, as well as the output of PP i , thus acting as upstream regulator to both of these important counter-regulated inhibitory pathways.
Given the reduction in Phospho1 expression shown here in Spp1 -/cells, we can interpret the reduction of TNAP activity in Spp1 -/mice as a combination of direct downregulation of the Alpl gene in the absence of OPN, as well as a downstream effect caused by the reduction in PHOSPHO1 expression caused by OPN deficiency. As indicated in our mass spectrometry data, the increased level of p-OPN peptides in Phospho1 -/mice is consistent with the expected hyper-phosphorylation status of OPN caused by the very low levels of TNAP activity in these Phospho1 -/animals. Thus, it seems clear that the prominent scoliosis phenotype of Phospho1 -/mice may be caused by the increased levels of OPN in the spine caused by the higher levels of Enpp1 expression in the spine and accumulation of p-OPN, due to the sharp reduction in TNAP activity resulting from PHOSPHO1 deficiency. Thus, in the Phospho1 -/model it is the accumulation of the mineralization inhibitor p-OPN that appears to cause the disease phenotype, rather than a build-up of PP i . Indeed, we previously showed that Phospho1 -/mice overexpressing TNAP under control of the ApoE promoter had high levels of plasma TNAP and normal plasma PP i but no significant correction of their skeletal phenotype. 3 In contrast, correcting plasma PP i levels in Alpl -/-HPP mice prevented all the skeletal and dental manifestations of this model of osteomalacia. 8 Thus, we have two skeletal dysplasias that display similar biochemical changes -elevation of both PP i and p-OPN concentrations -in which the hierarchical roles of these potent mineralization inhibitors appear to be different, with elevations in PP i largely explaining the HPP phenotype and elevations of p-OPN largely explaining the Phospho1 -/phenotype. Why did the transgenic overexpression of TNAP in the liver not lead to improvement of the Phospho1 -/phenotype? We think that this has to do with the fact that soluble circulating TNAP does not reach cartilage very well, possibly because of vascularity issues. Previous attempts to enzyme replacement therapy with plasma TNAP in the early 80's failed to yield life-saving treatment to children affected by severe HPP. [35] [36] The interpretation of those data has been that TNAP is needed locally at sites of initiation of matrix-vesicle mediated mineralization in the growth plate and in bone. The efficacy demonstrated by the use of mineral-targeting TNAP in the treatment of mice 8 and humans 37 with life-threatening HPP is consistent with that premise. In addition, our recent data examining Alpl -/mice bred to ApoE-Tnap or to Col1a1-Tnap transgenic mice expressing soluble TNAP, showed that while PP i was corrected in the plasma and the skeletal defect was improved, the animals still developed growth plate and joint abnormalities with age. 25 Those cartilage defects are not seen in mice treated with mineral-targeting TNAP. 8 We think that mineral-targeting TNAP is able to reach sites of impending mineralization in cartilage, while soluble TNAP is not. Thus, while the elevated levels of plasma TNAP achieved by the transgenic over-expression of TNAP in the liver is able to normalize plasma PP i concentrations, we think that the enzyme does not reach sites of impending mineralization in the growth plate where accumulated p-OPN is exerting its inhibitory influence in 
